RxDoctor Payments Data

Philip Patel, MD

Cardiovascular Disease · Rancho Mirage, CANPI 1104887447

Payments from drug & device makers

$155,679in general payments, 2019–2025

Across 235 payments — averaging $662.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$148K
  • Abbott$3K
  • Boston Scientific$3K
  • Edwards Lifesciences$287
  • Abiomed$182
  • E.r. Squibb & Sons, L.L.C.$148
  • plus $795 from 14 others

What the payments were for

  • Travel & lodging$1,04215%
  • Food & beverage$6,11685%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$155,679 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$812,528
Medicare patients
2,630
Services billed
18,344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis27$787,767
JardianceEmpagliflozin424$603,117
EliquisApixaban370$496,837
XareltoRivaroxaban264$381,195
Repatha SureclickEvolocumab276$324,439
VyndaqelTafamidis Meglumine12$311,444
EntrestoSacubitril/Valsartan210$225,648
Praluent PenAlirocumab94$83,665
FarxigaDapagliflozin Propanediol27$36,989
Ezetimibe642$22,827
MounjaroTirzepatide17$22,083
Repatha SyringeEvolocumab13$17,498
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide297$17,198
JanuviaSitagliptin Phosphate12$14,541
VerquvoVericiguat11$12,739

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis, Vyndaqel$21$1,596,049409 claims
Johnson & JohnsonXarelto$86$381,195264 claims
NovartisEntresto$98$225,648210 claims
MerckJanuvia, Verquvo$22$27,28123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Rancho Mirage

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →